

# Index

## A

- Anesthesia, monitoring depth  
of, 206, 218–219, 379
- Acid-base balance  
fluid and electrolyte management  
consequences on, 506–509  
maintaining, 504, 509–515
- Acid-base status, 508–509
- Actin, 33, 34, 38, 50, 51, 53–55, 58
- Action potential (AP), 30, 38–43, 45, 46, 50,  
107, 108, 424
- Activated partial thromboplastin time  
(APTT), 589
- Activated recombinant factor 7 (rFVIIa),  
267, 268
- Acute cholecystitis, 307
- Acute mesenteric ischemia, 307–308
- Acute pain management, 528, 529, 534, 538,  
539, 545, 553, 602
- Acute pancreatitis, 298
- Acute respiratory distress syndrome (ARDS),  
330, 339–342, 345–348, 463, 574,  
606, 608
- Adult cardiac surgery, 17, 108, 206–234,  
246–271, 298–311, 316–325,  
328–353, 366–380, 528, 575
- Afterload, 56, 57, 61, 82, 86, 94, 95, 178,  
283–286, 294, 309, 322, 332,  
333, 341, 344, 349, 352, 430, 544,  
567, 587, 602, 605, 612–614, 616,  
620, 622
- Alfentanil, 539–541
- Alpha 2 agonists, 542
- Alpha rhythm, 217
- Alprostadil, 76, 94
- Alternative modes, 340
- Analgesic agents, 108–115, 216–218, 538, 542
- Analgesic methods, 529, 534–535, 543,  
545–547, 551
- Anaphylaxis, 81, 85, 118, 455, 457, 460
- Angiotensin converting enzyme (ACE)  
inhibitors, 79, 95, 98, 288, 289, 317,  
319, 321, 427, 543
- Angiotensin II receptor antagonists (ARB's),  
95, 98, 321
- Anion gap, 440, 499, 512–513
- Anti-arrhythmic agents, 107–113
- Antibiotic prophylaxis, 129–131, 391, 393,  
595, 626
- Anticipated pain and experienced pain, 530
- Anticoagulants (oral and parenteral forms),  
119–125, 248–250
- Anticoagulation, 3, 4, 119–129, 291, 295, 301,  
302, 411, 529, 566, 568–569, 604,  
609, 624, 626
- Antidiuretic, 263
- Antifibrinolytic agents, 128–129,  
263–268, 625
- Antiplatelet agents, 119–128, 248–250, 626
- Arrhythmias, 2, 4, 31, 43, 51, 62, 86, 109, 111,  
145, 157, 164, 180, 287–288, 290,  
300, 301, 379, 406, 423, 469, 478,  
479, 481, 482, 504, 516, 519, 521,  
551, 572, 588, 605, 610, 614
- Arterial filter, 373, 570
- Atheroembolism, 318
- Auditory evoked potential (AEP), 206,  
219, 379
- Auto-i-PEEP, 341–342, 350
- Automated blood pressure measurement,  
144–145
- Axillary artery, 147–150, 152, 569, 576, 617

## B

- Bainbridge reflex, 59
- Balanced and unbalanced solutions, 461
- Baroreceptors reflex, 59–60
- Base excess, 437, 498, 507–509, 512
- Beta rhythm, 217

- Bezold-Jarisch reflex, 60–61
- Bicarbonate, 337, 422, 424, 432, 435, 439, 479, 496–499, 501–504, 506, 507, 510–513, 516–518
- Bioimpedance and bioelectance, 173, 185
- Bispectral index, 218
- Bleeding, surgical management of, 262, 269–271
- Blood circuit, 566–567
- Blood pressure, 59–62, 78, 79, 81–83, 85, 86, 90, 91, 93–95, 101, 144–148, 151, 153, 154, 157, 191, 192, 216, 217, 230, 232, 281–283, 285, 286, 290, 322, 342, 352, 353, 371, 435, 458, 470, 472, 505, 576, 584, 585, 614, 615
- Bloodstream infections (BSIs), 394–396, 627
- Body fluids, physiology of, 422, 464
- Boston rules, 511–512
- Brachial artery, 150, 173, 472
- Bradycardia, 101, 287, 413–415
- C**
- Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release (CICR), 47
- Calcium, 44–46, 48, 92, 97, 108, 294, 410, 423–424, 431, 432, 435, 436, 439, 445, 479–482, 505, 544, 545, 589  
homeostasis, 30, 34, 46–47
- Calcium channel blockers (CCBs), 98, 99, 285, 288, 289, 353
- Calibration, 10, 154, 180, 184, 234, 281, 471, 472
- California discharge database, 18
- Cannulation, 146–153, 159, 270, 271, 290, 295, 296, 318, 370, 531, 569, 575, 576, 607, 617, 618
- Cardiac action, 31
- Cardiac anesthesia, 2–3, 601, 605
- Cardiac complications, 284–288
- Cardiac cycle, 46, 55–58, 294
- Cardiac output (CO), 3, 35, 49, 56, 57, 61, 78, 79, 83–86, 93–95, 102, 109, 146, 151, 166, 168, 171–175, 177–180, 182–185, 188, 190, 191, 206, 222, 270, 283–286, 289, 292, 294, 300, 301, 310, 318, 322, 323, 352, 541, 573, 585–587, 609, 622  
monitoring, 171–192
- Cardiac physiology, 32, 33, 36, 40–44, 55, 57
- Cardiac reflexes, 58–63
- Cardiac surgery, 2, 10, 76, 154, 298–302, 304–309, 311, 420, 504, 528, 601, 610, 656
- cardio-pulmonary resuscitation after, 291–293
- CNS dysfunction after, 366
- post-operative ICU setting  
acid-base balance, basis of pathophysiology, 504–505  
fluid and electrolyte, basis of pathophysiology, 429–431  
pulmonary response to general anesthesia and, 333–334
- Cardiac surgery patients  
clinical impact in, 473  
malnutrition, 656
- Cardiac work, 55–58, 81, 86, 93
- Cardiogenic shock, 17, 81, 91, 92, 293, 295, 335, 341, 430, 604, 605
- Cardiology, 588
- Cardiomyocytes, 28–31, 34, 37–40, 43–49, 53, 54, 56, 58, 86
- Cardioplegia, 414, 478, 569–570
- Cardiopulmonary bypass  
cardiopulmonary bypass-related complications, 571–577  
circuit structure, 566–571  
CPB related equipment, 374  
CSA-AKI, management of, 321
- Cardio-pulmonary interactions, 332–333
- Cardiotomy, 370, 373, 566, 568, 570, 573
- Cardiovascular, 3, 20, 59, 79, 81, 86, 94, 107, 112, 144–192, 268, 281–296, 302, 307, 392, 413, 430, 438, 451, 465, 466, 480, 530, 535, 548, 606, 609–620, 661  
pharmacology, 77, 83, 89, 90, 97–102, 106, 113, 115–119, 123, 127–131, 538
- Cardiovascular system, 191, 537
- Catheter-related infections, 395
- Central venous pressure (CVP), 61, 154, 155, 164, 168, 191, 270, 281, 282, 290, 291, 293, 321, 322, 459, 467, 470, 567, 585, 587, 611, 612, 616, 622
- Central venous pressure curve, 155, 168
- Cerebral oximetry, 3, 192, 206, 220–223, 371, 604
- Chemoreceptor reflex, 62–63
- Chloride, 213, 424, 432, 435–437, 439, 445, 452, 461, 479, 504, 506, 508, 509, 537
- Cholecystitis, 298
- Chordae tendineae, 27
- Chronic thoracic chest pain or chronic leg pain, 532
- Circulatory assist device, 293–296

- Classification, 28, 50, 76, 107, 108, 366, 368, 369, 375, 376, 434–435, 439, 447–448, 532  
of CNS injuries, 366–368  
and mechanisms of CNS dysfunction after cardiac surgery, 366–372
- ClearSight system, 190
- Clostridium difficile* infection, 119, 299, 395–397
- Clotting disorders, 438, 446
- CNS injuries, mechanisms and potential etiologies of, 369–374
- Coagulation  
and bleeding, physiology of, 246–248  
and platelet function, 451–452
- Coagulopathy, 3, 4, 147, 155, 248, 250, 251, 269, 303, 308, 457, 458, 553, 570, 572, 577, 584, 588–590, 592, 625, 626
- Colloids, 287, 321, 349, 428, 429, 432, 439–440, 443–448, 450, 451, 453–458, 473, 482, 508–509, 567, 587  
physiological properties of, 439
- Colonic pseudo-obstruction, 303, 305
- Communication systems, 634–643
- Compartment syndrome, 145, 146, 148, 150, 309
- Complications, 20, 80, 82, 84, 86, 93, 94, 117, 120, 147–153, 156, 158, 160–164, 170–171, 225, 258, 260, 262, 267, 271, 316–325, 328–353, 366–370, 373, 388, 391, 392, 406, 413, 429, 431, 436, 451, 462, 463, 471, 472, 476, 479, 480, 508, 515, 517, 520, 522, 534–536, 538, 543, 546, 547, 549–552, 567, 572, 575–577, 584, 587, 594, 606–608, 616, 617, 619, 623, 624, 626, 640  
of central venous catheter, 225  
of mechanical ventilation, 336
- Composition and concentration, 441
- Compressed spectral array-acute kidney injury (CSA-AKI), strategies for renal protection and management of, 320–322
- Continuous renal replacement therapy, 154
- Contractility, 30, 46, 57, 59–62, 77, 81, 83, 86, 91, 283, 286, 430, 508, 586, 611, 612, 614–619, 622
- Coronary arteries, 18, 35–37, 60, 94, 145, 281, 284, 293, 370, 431, 457, 576–577, 584
- Crew resource management (CRM), 643, 645–646, 649
- Cryoprecipitate, 251, 258, 264–266, 268, 269
- Crystalloids, 211, 321, 428, 429, 432, 434–439, 441, 442, 453–456, 459, 475, 482, 508, 567, 569, 571, 587  
and colloids, 456
- Culture, 130, 153, 170, 351, 390, 392, 394, 395, 401, 595, 627, 634–637
- Cushing, Harvey, 61
- Cushing reflex, 61–62
- D**
- Daily multidisciplinary patient-centered rounds, 638–643
- Deep sternal wound infection (DSWI), 21, 281, 300, 391–394, 609
- Definition and staging, 316–317  
The descriptive approach, 497–498
- Dextrans, 439, 443–445, 457, 458
- Dilution acidosis, 437, 506, 508, 513
- Direct consequences, 336
- Discontinuation of mechanical ventilation, 343–344
- Disturbance, 610
- Diuretics, 78, 79, 91, 98–100, 317, 322–324, 341, 349, 476, 478, 479, 481, 482, 514, 515, 518, 519, 542, 543, 587, 591, 608, 621, 622
- Dobutamine phosphate, 92
- Donor organ considerations, 583–584
- Dopamine hydrochloride, 82
- Dorsalis pedis artery, 147, 150, 152
- Dysphagia, 303, 305
- E**
- Ejection fraction, 20, 56, 57, 283, 284, 286, 300, 335, 350, 604
- Electroencephalography (EEG)  
including multichannel or uni-channel EEG, 206, 210–218, 379  
normal and abnormal, 215  
spectrogram, 218
- Electrolyte management, 474–482, 506, 588
- Electrolyte modifications, 431, 437
- Endocardium, 28
- Endocrine, 423, 530, 624
- Endomyocardial, 582, 585, 593, 594
- Endothelin receptor blockers, 106
- Epidemiology, 17, 298–300, 316
- Epidural, 452, 534, 536, 541, 546, 548, 549, 551–553, 602

- Epinephrine, 76, 80–82, 85–87, 283, 287, 288, 293, 310, 322, 350, 433, 542, 586, 614, 615
- Esophageal Doppler, 173, 175–178, 471, 473
- Esophagitis, 303, 305–306
- Etiologic factors aggravating pain, 531–532
- EuroSCORE, 21–22, 281, 289, 577
- Evoked potentials, somatosensory evoked potentials, 219
- Excitation-contraction coupling (ECC), 30, 34, 38, 43–48
- Exposure to CPB, 318–319
- F**
- Factor eight inhibitor bypass activity (FEIBA), 265, 267
- Femoral artery, 147, 148, 152, 160, 294, 569, 618, 619
- Fentanyl, 2, 114, 538–541, 601, 603
- Fibrinogen, 128, 247, 251, 258, 264–266, 269
- Fibrinogen level, 265, 266, 452, 589
- Fick principle, 172
- FloTrac/Vigileo, 179, 472
- Fluid, clinical management of, 431–434
- Fluid movement through capillary membranes, 427–429
- Frank-Starling relationship, 54, 56–58
- G**
- Gabapentin, 545, 603
- Gamma rhythm, 217
- Gap junction, 30, 31, 34, 35, 38
- Gas exchange, 175, 331, 334, 337, 342, 345, 346, 350, 566, 575, 605–608
- Gastritis, 303, 305–306
- Gastrointestinal bleeding, 306, 309, 335, 624
- Gastrointestinal complications, 281, 298–311, 543  
mechanical assist devices, 309
- Gelatin, 439, 443, 445–446, 449, 457–461, 509
- General principle, 262, 299, 320–321, 595
- Goal-directed fluid therapy, 464–473
- Goodness of fit, 10–12
- H**
- Handoff protocol, 637–638
- Heart disease, 32, 33, 36, 40–42, 77, 83, 89, 90, 94, 97–102, 106, 107, 110, 113, 115–119, 123, 127–131, 282, 318, 352, 411, 537, 577, 658
- Heart-kidney transplantation, 591
- Heat exchanger, 295, 566, 570
- Hematologic effect, 572
- Hemodynamic parameters, normal values for, 192
- Hemorrhage, 79, 86, 146, 171, 207, 260, 298, 301, 306–309, 338, 342, 429, 458, 475, 515, 543, 575, 588–590, 594
- Heparin induced thrombocytopenia (HIT), 125, 153, 259–262, 311, 626
- Hepatic congestion, 592, 622–623, 625
- Hepatotoxicity, 106, 111, 301, 543, 592
- High flow oxygen, 344–345, 402
- His bundle, 35, 39
- History, 2–4, 84, 234, 286, 288, 302, 305, 306, 309, 371, 375, 408, 455, 532, 537, 540, 543, 566, 575, 605, 607, 622
- Human prothrombin complex (PCC), 265–267
- Hydralazine, 76, 93–94, 100, 102
- Hydroxyethyl starches, 431, 439, 443, 446–455  
and other colloids, 458–461
- Hyperchloremic acidosis, 506
- Hypertonic colloid solutions, 455
- Hypertonic crystalloids, 438–439
- Hypotension, 88
- I**
- Ileus, 114, 115, 298, 302–305, 463
- Immunosuppression, 398, 399, 594–595, 602
- Incidence and prognosis, 406, 411, 413–414
- Indirect consequences, 336
- Infection, 4, 117, 129, 147, 148, 150, 151, 153, 158, 163, 167, 225, 295, 300, 302, 309, 319, 350, 351, 388–391, 394–402, 461, 471, 533, 547, 595, 607, 612, 624, 627
- Infectious considerations, 151
- Infectious diseases in post-cardiac transplant recipients, 397–399
- Inflammation, 151, 301, 304, 305, 318, 324, 334, 349, 351, 370, 390, 394, 406, 429, 430, 440, 451, 466, 571–572, 574, 658
- Inotropes, 76, 303, 310, 322, 335, 338, 349, 430, 469, 472, 505, 551, 586, 587, 606–608, 612–616, 618, 621, 622, 624, 627, 657
- Inotropic agents, cardiovascular effects of, 283–284
- International normalized ratio (INR), 248, 251, 267, 268, 589, 626

- Intrapleural infiltration of local anesthetics, 546–548
- Intrathecal, 534, 536, 538, 539, 541, 542, 546, 548, 550
- Intravenous anesthetic agents, 108–115
- Invasive blood pressure (IBP) monitoring, 145–154, 192
- Ionic balance, 422–424
- Ischemia and Ischemia-reperfusion injury, 318
- J**
- Jugular vein oxygen saturation (SjVO<sub>2</sub>), 223–228, 380
- K**
- Ketamine, 374, 544
- Kidney dysfunction, 113, 316, 318–320, 323, 324, 436, 453–455, 512, 573
- Korotkoff, 144, 145
- L**
- Latest-generation crystalloids, 437, 508
- Levophed, 85
- Levosimendan, 76, 86–93, 294
- Liberal vs. restricted approach, 462–464
- LiDCO® system, 174, 180
- Liver dysfunction, 308, 592
- Low cardiac output, 3, 87, 92, 96, 190, 282–287, 295, 300, 301, 307–309, 322, 369, 573, 574, 622, 661
- Low cardiac output state (LCOS), 91
- M**
- Magnesium, 113, 288, 374, 408, 409, 423, 424, 431, 432, 435, 436, 439, 481–482, 544, 658
- Magnesium sulfate, 113, 409, 544
- Management, 3, 4, 32, 33, 36, 40–42, 44, 77, 79, 83, 89, 90, 97–102, 104–108, 113, 115–119, 123, 127–131, 154, 208, 246, 258, 261–263, 269, 281–296, 299, 302, 305, 306, 308–311, 316–325, 328–353, 367, 372, 373, 375, 376, 406, 408–412, 414–415, 420–493, 497, 500, 505, 509, 516, 521, 522, 528, 573, 576, 582, 584, 585, 587–592, 594, 596, 601, 602, 604–606, 608, 609, 611, 618, 619, 621–623, 636, 638, 643
- Mean arterial pressure (MAP), 301
- Mechanical ventilation, 3, 129, 163, 271, 300, 301, 305–307, 328, 330, 332, 335–346, 350, 351, 376, 377, 462, 465, 468, 473, 476, 505, 517, 522, 539, 571, 590, 601, 606, 657
- in specific scenarios, 345–346
- during VV ECMO for ARDS, 346
- work of breathing on, 342–343
- The Medicare Provider Analysis and Review (MedPAR), 17
- Medical nutrition therapy
- and nutritional support protocols, 657–658
- in pediatric cardiac surgery, 658–661
- Membrane oxygenator, 295, 566, 568, 570, 576
- Mesenteric ischemia, 290, 298, 303, 305, 308, 309, 623
- Metabolic acidosis, 79, 283, 308, 324, 342, 432, 436, 437, 459, 497–499, 504–519, 522, 523, 570, 623
- Metabolic alkalosis, 99, 479, 497, 498, 504, 510–515, 517–520
- Metabolizable anions and base excess, 507
- Milrinone lactate, 86
- Minimal invasive extracorporeal circulation (MiECC), 570–571
- Model validation, 12
- Monitoring, 3, 8, 78, 84, 103, 106, 108, 110–112, 121–125, 127, 144–192, 206–234, 246–271, 282–284, 287, 290–292, 308, 310, 321, 322, 343, 376, 437, 462, 465, 467, 471–473, 508, 540, 570, 584, 585, 587, 589, 591, 592, 618, 619, 637, 644, 645
- Motor evoked potential (MEP), 206, 219, 379
- Mycobacterium chimeria* infection, 398–390
- Myocardium, 28–31, 50, 51, 57, 58, 83, 88, 117, 283, 286, 293, 352, 408, 478, 479
- Myosin, 32–34, 38, 50, 51, 53–55, 58
- Myosin binding protein C, 50, 51, 55
- N**
- National inpatient sample (NIS), 18–19
- Natural colloids, albumin (HA), 440–443
- Near-infrared spectroscopy technique (NIRS), 192, 206, 220, 221, 379
- Nephrotoxins, 317, 319
- Neuraxial blocks, 543, 548–553
- Neurologic monitoring, 379–380, 576
- Neuromuscular blocking agents, 118, 174, 298
- New York Heart Association (NYHA), 20

- New York State Department of Health (NYS DOH), 19
- Nitric oxide (NO), 93, 94, 97, 102–104, 289, 346, 353, 586, 587, 590, 613, 614
- Nitroglycerin, 76, 93, 96, 100, 103, 285, 353, 586, 613, 614
- Non-invasive, 144–145, 171, 175, 178, 188, 228, 344–345, 350, 472
- Non-invasive ventilation, 340–341, 517
- Non-invasive systems, 173
- Non-steroidal anti-inflammatory drugs (NSAID's), 306, 319, 534, 535, 542–544, 603
- Norepinephrine bitartrate, 85, 586
- Normal saline solution, 436, 457, 508
- Novel oral anticoagulants, 119, 411
- Nutritional status screening, 656
- O**
- Observed-to-Expected ratio, 13
- Obstructive airway disease, 342, 349–350
- Oculocardiac reflex, 62
- Off-pump coronary artery bypass, 473, 576–577
- Opioid, 114, 115, 287, 303, 304, 307, 518, 533–546, 550, 551
- Orthotopic heart transplantation, 414, 582
- Osmolar balance, 424–427, 503, 504
- Outcome, 3, 8–23, 49, 50, 57, 79, 120, 164, 165, 177, 190, 206, 207, 221, 225, 228, 246, 259, 268, 269, 271, 281, 289–291, 294, 295, 308, 316–319, 323, 325, 339–342, 345, 351, 366–368, 370–372, 375, 379, 411, 429, 439, 441, 451, 453, 455, 460, 461, 463, 468, 470, 471, 473, 528, 532, 537, 543, 548–551, 570, 572, 573, 576, 577, 582, 583, 586, 592, 594, 596, 601, 625, 637, 643, 644, 646, 649, 658, 660, 661
- Oxygen and ventilation goals, 342
- P**
- Pancreatic, 660
- Pancreatitis, 298, 304, 305, 309
- Paracetamol, 543–544
- Paravertebral block, 534, 548–550
- Partial carbon dioxide (CO<sub>2</sub>) rebreathing, 173–175
- Partial thromboplastin time (PTT), 249, 251, 252, 291, 626
- Pathogenesis, 47, 298, 317, 406, 411, 413–414, 480
- Pathophysiology, 300–301, 305, 317–320, 325, 482, 499, 530–531, 574, 611, 624
- Patient controlled analgesia, 534, 540, 544–546
- Patient safety, 284, 634–638, 640, 643, 645, 647, 649
- Patient satisfaction and patients' expectations, 530
- Patient-controlled analgesia (PCA), 534, 540, 544–546
- Performing spontaneous breathing trials, 344
- Pericardium, 27, 162, 263, 332
- Pharmacokinetics
  - distribution and duration of action, 434–436
  - distribution, elimination, and duration of action, 441, 444, 449–450
  - distribution, elimination, and duration of effect, 446
- Pharmacologic alternatives, 535–546
- Pharmacologic neuroprotection, 374
- Pharmacology, 2, 76–131
- Phentolamine, 76, 86, 95
- Phentolamine mesylate, 76, 95, 97
- Phenylephrine hydrochloride, 77
- Phosphodiesterase 5 (PDE 5) inhibitors, 103–106
- Physical and chemical properties, 432–434
- Physiologic anatomy, 26–35
- PiCCO® system, 180
- Platelet count, 249, 251, 258–260, 267, 268, 270, 441, 572, 589, 622, 624
- Pleural effusions, 4, 270, 281, 334, 347, 351, 475, 517, 520, 606–608
- Pneumonia and ventilator associated events, 350–352
- Pneumothorax/hemothorax, 348–349
- Positive end, 589
- Positive end-expiratory pressure (PEEP), 301, 341
- Posterior tibialis, 150
- Post-operative cardiac tamponade, 290–291
- Post-operative care, 2–4, 144–192, 206–207, 230, 234, 325, 529
- Postoperative CNS injuries, time based classification, 368
- Postoperative hemodynamic instability, 285–287
- Postoperative management, 396
- Postoperative myocardial infarction, 281
- Postoperative pain, 528–553

- Postoperative strategies to reduce respiratory failure, 338–339
- Post-transplant monitoring, 585
- Potassium (K), 92, 100, 108, 288, 289, 412, 423, 431, 432, 435, 436, 439, 478–479
- Potential risks and side effects, 437–438, 442–446, 451–455
- Pregabalin, 545, 603
- Preload, 56, 57, 61, 86, 93, 154, 174, 180, 282–286, 294, 295, 322, 333, 341, 430, 467, 468, 470, 471, 567, 585, 587, 589–591, 605, 611–612, 616
- Preoperative risk stratification, 310, 336–337
- Pressure control ventilation, 339–340
- Pressure recording analytical method, 183
- Pressure support, 340, 344, 605, 607
- Prevention strategies, 374
- Primary graft dysfunction (PGD), 587–588
- Propensity score analysis, 9, 13–16
- Prophylaxis, 84, 117, 119, 120, 122, 124, 125, 131, 302, 311, 391, 393, 399, 402, 408–409, 412, 414, 595, 607, 624
- Prostaglandin E1, 94, 97
- Prothrombin time (PT), 122, 251, 622
- Pulmonary artery (PA), 96  
pressure monitoring, 165–171
- Pulmonary artery catheter (PAC), 3, 157, 173, 223, 224, 281, 285, 287, 349, 396, 471, 585, 587, 605
- Pulmonary edema, 321, 330, 331, 340, 341, 344, 345, 349, 351, 429, 430, 437, 442, 451, 457, 463, 476, 482, 517, 520, 606–608, 610, 612, 615, 618, 619
- Pulmonary hypertension, 80, 91, 95, 97, 102–107, 165, 282, 288, 331, 342, 352–353
- Pulse contour analysis, 173, 178, 180, 182, 192
- Q**
- The quantitative approach, 499–502
- R**
- Radial artery, 147–148, 150–152
- Ramsay sedation scale (Ramsay), 108, 210
- Reducing postoperative respiratory failure, 336–339
- Regional anesthetic techniques, 546
- Regitine, 95
- Relation among fluid, electrolyte, and acid-base balance, 502–504
- Remifentanyl, 114, 539–541, 601
- Renal replacement therapy (RRT), 155, 316, 319–324, 453, 454, 460, 572, 577, 606, 621, 622
- Respiratory acidosis, 353, 498, 510, 512, 514, 517, 520–521
- Respiratory alkalosis, 505, 510–512, 514, 517, 522
- Respiratory failure, intraoperative management to reduce, 337–338
- Respiratory mechanics, 328–331, 574
- Respiratory physiology and pathophysiology, 328–335
- Rhythm disturbances, 81, 287, 288, 583, 584, 588, 624
- Richmond agitation sedation scale (RASS), 108, 208, 209, 603
- Ringer's lactate and Ringer's acetate, 436, 508
- Risk, 8–23, 57, 86, 206, 207, 246, 281, 299, 302, 305, 306, 308–310, 316, 334, 388, 408, 430, 504, 529, 535, 551, 573, 603, 646, 656
- Risk factor, 22, 117, 289, 309, 338, 371, 372, 375, 376, 391, 409, 573, 574, 656
- Risk factors, 19, 22, 117, 129, 151, 260, 269, 270, 289, 298–300, 302, 305, 308, 309, 319, 334, 338, 348, 350, 368, 369, 371–373, 375, 376, 389–393, 396, 409, 453, 530–532, 538, 573, 574, 622, 625, 656  
and biomarkers, 319  
of CNS injuries, 368–369  
for postoperative respiratory failure, 334–335
- Risk modeling, 9–10
- Risk-adjusted comparison metrics, 12–13
- Riva-Rocci, 144, 145
- Rotational thromboelastography (ROTEM), 252–255, 258
- S**
- Sarcolemma, 29, 30, 47, 48
- Sarcoplasmic reticulum (SR), 29, 30, 34, 44, 45, 48, 49
- Sedation agitation scale (SAS), 108, 208–210
- Sedative drugs, 108–116
- Sedillot's triangle, 156, 157, 159
- Sheet desmosomes, 30, 31
- Simulation, 4, 646–649
- Society of Thoracic Surgeons (STS)  
cardiac surgery risk calculator, 21  
Adult Cardiac Surgery Database (ACSD), 20–21

- Sodium, 80, 422, 424–427, 431, 432, 435–439, 463, 474–478, 481, 503, 504, 506, 509, 515, 517, 518
- Sodium nitroprusside (SNP), 76, 94–95, 285, 353
- Spinal, 177, 219, 535, 536, 542, 545, 550–551, 553
- Spot desmosomes, 30, 31
- Spontaneous breathing trial (SBT), readiness for, 343–344
- Standard base excess (SBE), 499, 512, 520
- Sternal wound infection, 271, 300, 334, 335, 393
- Stewart approach, 503, 506, 509, 513–515, 519
- Storing and itching, 455
- Strategies for managing specific perioperative disease states, 347–353
- Stress ulcer, 115–119, 609
- Sufentanil, 539–541
- Superficial temporal artery, 151
- Supraventricular tachycardias, 406–411
- Surgical site infection (SSI), 129, 388–391, 393, 402, 627
- Swan-Ganz, 165, 471
- Synthetic colloid, 439, 442, 443, 449
- Systemic afterload, 613–614
- T**
- T tubule, 29, 34, 44–46, 49
- Team performance, 643–649
- TeamSTEPPS, 643, 644
- Thromboelastography (TEG), 252–255, 589
- Thrombolytic agents, 119, 128
- Titin, 50, 51, 55
- Transcranial Doppler (TCD), 205–234, 380
- Transplant, 398, 399, 582, 584, 585, 587, 588, 590–594, 617, 618, 621, 660
- Transpulmonary bolus thermololition, 173
- Transpulmonary lithium indicator dilution, 174
- Tropomodulin, 50, 53, 55
- Tropomyosin (TM), 32, 33, 50, 53–55
- Troponin, 32–34, 50, 53–55, 284, 320, 349
- Type I and type II injuries, 367
- U**
- Ultrafiltration, 571, 572, 575
- Ultrasonic cardiac output monitor, 173, 188, 190
- Ultrasound guided CVC insertion, 160
- V**
- Valsalva maneuver, 61
- Vasoactive agent, 76–102, 148, 592
- Vasoplegic syndrome, 289–290
- Vasopressin, 76, 78–80, 89, 96, 289, 290, 301, 310, 322, 586, 590, 614
- Ventilation, 300  
     modes, 339–343  
     and perfusion, 331–332
- Ventricular arrhythmias (VA), 409–413
- Ventricular tachyarrhythmias, 610
- Veterans Administration Database, 20
- Visual-evoked potential (VEP), 219
- Volatile anesthetics, 114, 117
- Volume control ventilation, 339
- W**
- Water distribution modification, 429–431, 437
- Which kind of fluid?, 432
- Z**
- Zeroing, 153, 168